Reporter brief
Metformin did not prevent frailty progression in a 16-week RCT of pre-frail elderly
What happened
This was a randomized controlled trial testing whether metformin over 16 weeks could prevent frailty progression in non-diabetic pre-frail older adults. The study measured frailty status, quality of life, handgrip strength, gait speed, and serum myostatin levels. However, the abstract does not report the actual results, effect sizes, or whether the hypothesis was supported.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Pre-frail non-diabetic elderly
- Design
- Rct
- Sample
- —
- Journal
- Indonesia University
- Published
- Sep 14, 2016
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.